Active	Status	Sponsor type	Region	Phase	Filter
3 Active 12 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Fludase (oplunofusp) / Ansun Biopharma
NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study	Recruiting	3	274	Europe, US, RoW	DAS181, Placebo, DAS181 COVID-19, DAS181 OL	Ansun Biopharma, Inc.	Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19	08/25	08/25
STOP Flu, NCT04298060: DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)	Not yet recruiting	2b	280	RoW	DAS181, Placebo	Ansun Biopharma, Inc.	Influenza Infection, SAD-RV Infection and COVID-19	03/21	09/22
NCT04460547: Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic	Not yet recruiting	N/A	200	NA	Convalescent Plasma Transfusion, Hydroxychloroquine, DAS181, Ivermectin, Interferon Beta-1A	Qassim University	COVID-19	08/20	09/20